CC
IRWD icon

Checkpoint Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Checkpoint Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500,000
Closed -$5.72M – 21
2023
Q4 		$5.72M Buy
+500,000
New +$4.95M 3.46% 10

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Checkpoint Capital's IRWD Position: Q2 2024 in Review

Checkpoint Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2024, closing a stake of 618,528 shares — an estimated $5.39M sold.

Checkpoint Capital first reported a position in IRWD in Q4 2023 and held it in 2 quarters. The position peaked at $10.1M in Q4 2023. 226 funds tracked by Wall St. Rank hold IRWD as of Q2 2024.

  • Checkpoint Capital reported no remaining Ironwood Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Checkpoint Capital sold 618,528 Ironwood Pharmaceuticals shares in Q2 2024, an estimated $5.39M.
  • Checkpoint Capital first reported a position in Ironwood Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Checkpoint Capital's Ironwood Pharmaceuticals position peaked at $10.1M in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2024.

Based on Checkpoint Capital's 13F filing for Q2 2024, filed 14 Aug 2024.